Milestone Pharmaceuticals (MIST) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Milestone Pharmaceuticals is gearing up for the potential FDA approval of its CARDAMYST nasal spray for PSVT, with a decision expected by March 2025. The company’s partner, Corxel, reported positive Phase 3 trial results in China, showing significant efficacy in converting PSVT to sinus rhythm. Milestone is actively preparing for a commercial launch and expanding its clinical trials to improve patient care.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
